- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01984164
CAndesartan vs LIsinopril Effects on the BRain (CALIBREX)
February 2, 2021 updated by: Ihab Hajjar, Emory University
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)
The aim of this study is to conduct a 1-year double blind randomized control trial comparing candesartan to lisinopril in 140 individuals with hypertension and executive mild cognitive impairment in their effects on executive function, neuroimaging markers, and vascular indicators.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Hypertension is associated with cognitive impairment even in the absence of clinical dementia. To date, no specific treatment is available for this pattern of mild cognitive impairment related to hypertension.
- Objectives or purpose: The aims of this study are to investigate the effects of candesartan on executive function decline and on changes in cerebral perfusion, cerebrovascular reserve and microvascular brain injury. The study also intends to identify potential underlying mechanisms related to vascular structure and function, including atherosclerosis, vascular inflammation, vascular stiffness, and endothelial progenitor cells, by which candesartan may affect the cognitive and cerebrovascular outcomes.
- Study methodology:This is a double blind randomized clinical trial that will be conducted in 140 individuals (70 in the candesartan group, 70 in the lisinopril group). Our target population is subjects: 55 years or older with hypertension and Executive Mild Cognitive Impairment.
- Endpoints to be measured:Our measures include cognitive function, cerebral perfusion and reserve, markers of vascular brain damage, atherosclerosis, stiffness, vascular inflammation and endothelial function.
- Description of intervention, follow-up, and duration of study: Eligible participants will undergo randomization into 2 groups and will be seen frequently until their blood pressure is controlled (<140/90 mmHg). Participants will be seen at 3, 6 and 12 months afterwards.
Study Type
Interventional
Enrollment (Actual)
176
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Emory Univeristy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
53 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age: 55 years or older;
- Hypertension: SBP≥140 mm Hg or DBP≥ 90 mm or receiving antihypertensive medications.
Executive MCI will be defined using these criteria:
- The Montreal Cognitive Assessment (MoCA) score less than or equal to 26
- Executive dysfunction: A performance at the 10th percentile or below on at least one of four screening tests for executive function: Trail Making Test, Part B (TMT-B), modified Stroop interference, Digit Span and Digit Sequencing, and Letter fluency.
- Minimal Functional limitation as reflected by the Functional Assessment Questionnaire (FAQ)≤7
Exclusion Criteria:
- Intolerance to study drugs;
- SBP >200 or DBP >110 mm Hg;
- Renal disease or hyperkalemia
- Active medical or psychiatric problems
- Uncontrolled congestive heart failure;
- History of stroke in the past 3 years;
- Inability to perform the study procedures
- Women of childbearing potential
- diagnosis of dementia
- In those who lack decision capacity, a study surrogate who can sign on their behalf will be required. Since we are enrolling only those with MCI, we anticipate that most participants will have decision capacity
- Current use of Lithium, as most antihypertensive classes may lead to increased lithium toxic levels.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Candesartan
To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg.
Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg.
Antihypertensive medications will be increased every 2 weeks until control is achieved.
|
blinded
Other Names:
|
Active Comparator: Lisinopril
To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg.
Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg.
Antihypertensive medications will be increased every 2 weeks until control is achieved.
|
Blinded
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Executive Function
Time Frame: 12 months
|
Executive function will be assessed using Trail Making Test (part B-A).
Part A was collected to correct for motor speed and visual-perceptual demands on TMT by subtracting completion time for TMT Part A from completion time for Part B (TMT B - A). TMT Part B-A provides a relatively purer measure of executive functioning.
It has a timed scale from 0 sec (min) to 300 secs (max).
Along this scale, a lower score is better.
|
12 months
|
NINDS-initiated EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or "EXAMINER" Tool Box.
Time Frame: 12 months
|
EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or "EXAMINER" tool box.
This test batteryThe battery includes 11 tasks that generate 15 primary variables.
Within this set, the EXAMINER includes: working memory, inhibition, set shifting, and fluency.
The parts of EXAMINER that were used for this study include: Flanker task (inhibition) which involves responding to a central stimulus while ignoring flanking stimuli that are either compatible or incompatible with the central stimulus; Set-shifting, a measure of mental flexibility; Spatial 1-Back test assesses spatial working memory; Dot Counting test assesses verbal working memory; Verbal Fluency tested using a List Generation test which require the participant to generate words beginning with a specific letter, and category fluency in which the participant generates words from a specified category (e.g., animals, fruits).
Higher are reflective of better executive function (-1 to +1)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Memory
Time Frame: 12 months
|
To assess episodic memory, the Hopkins Verbal Learning Test-Revised (HVLT-R) will be used.
The retention (%) score is calculated by dividing the delayed recall trial by the higher of 3 learning trials.
Each trial scores 0 (min) to 12 (max).
The HVLT-R retention score is a percentage, and a higher percentage represents a better outcome.
|
12 months
|
Language
Time Frame: 12 months
|
This will be measured using the Boston Naming Test.
BNT is a neuropsychological test used to assess visual confrontation naming and language performance in participants with cognitive decline.
Its short 15-item version consists of drawings of objects ranging from common objects to less familiar objects.
Scale: 0 (min score) to 15 (max score).
For this test, a higher score/response represents a better outcome.
|
12 months
|
Attention Measured Using Digit Span Backward
Time Frame: 12 months
|
The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scales (WMS).
For the digit span backwards, subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in reverse order (backward span).
Backward span is an executive task particularly dependent on working memory.
The Digit Span backward is scored for backwards performance.
Scale: 0 (minimum) to 16 (maximum).
A higher score represents a better outcome.
|
12 months
|
White Matter Lesion Volume
Time Frame: 12 months
|
White Matter Lesion volume: high-resolution anatomical images are acquired for the measurement of microvascular disease.
WMH volumes will be obtained from Fluid attenuated inversion recovery (FLAIR) imaging sequence and reported as total volume (in mm3).
Higher values means greater WMH
|
12 months
|
Cerebral Perfusion
Time Frame: 12 months
|
ASL-MRI: Arterial Spin Labeling (ASL) MRI is non-invasive measure of perfusion that does not require contrast, and allows multiple brain regions mapping of perfusion and reserve.
ASL-MRI provides measures of cerebral blood flow (CBF).
Higher values indicates higher CBF.
|
12 months
|
Attention Measured Using Digit Span Forward
Time Frame: 12 months
|
This will be measured using Digit Span Forward.
The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scales (WMS).
For the digit span forward, subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in the correct order (forward span).
Forward span captures attention efficiency and capacity.
The Digit Span forward is scored for forwards performance.
Scale: 0 (minimum) to 16 (maximum).
A higher score represents a better outcome.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ihab Hajjar, MD, MS, Emory Univeristy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 20, 2014
Primary Completion (Actual)
December 3, 2018
Study Completion (Actual)
December 3, 2018
Study Registration Dates
First Submitted
October 27, 2013
First Submitted That Met QC Criteria
November 7, 2013
First Posted (Estimate)
November 14, 2013
Study Record Updates
Last Update Posted (Actual)
February 21, 2021
Last Update Submitted That Met QC Criteria
February 2, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Protective Agents
- Cardiotonic Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Candesartan
- Lisinopril
Other Study ID Numbers
- IRB00070087
- R01AG042127 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Candesartan
-
GlaxoSmithKlineCompleted
-
AstraZenecaCompletedNon-diabetic Nephropathy With HypertensionKorea, Republic of
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedCardiovascular DiseaseIndia
-
St. Olavs HospitalUllevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaboratorsActive, not recruiting
-
TakedaCompleted
-
Huazhong University of Science and TechnologyUnknown
-
AstraZenecaTakedaCompleted
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyTerminatedChronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) LevelGermany, France, Netherlands
-
AstraZenecaCompleted